Kanabo Group PLC
LSE:KNB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
TORIDOLL Holdings Corp
TSE:3397
|
JP |
|
J
|
Jiangxi Ganyue Expressway Co Ltd
SSE:600269
|
CN |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| UK |
|
Kanabo Group PLC
LSE:KNB
|
1.4m GBP |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
871.6B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.4B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
296.9B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
231.4B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
155.5B USD |
Loading...
|
|
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
89.3B GBP |
Loading...
|
Market Distribution
| Min | -1 510% |
| 30th Percentile | 0.4% |
| Median | 0.5% |
| 70th Percentile | 0.7% |
| Max | 7 323.1% |
Other Profitability Ratios
Kanabo Group PLC
Glance View
Kanabo Group Plc engages in the acquisition of a target company and business in the energy and industrial sectors. The firm is principally focused on distribution of cannabis-derived products for medical patients, and non- tetrahydrocannabinol (THC) products for Cannabidiol (CBD) consumers. The company has developed a formula for sleep disorders (insomnia), three CBD formulations for Reload, Relax, and Repair, and the VapePod, which is a vaporization delivery system for cannabis extract. The firm's R&D lab is set up in the Weizmann Science Park. The firm's clinical and validation activities, including safety and efficiency tests, are conducted in Israel. The firm is selling its initial products in Europe. The company is also engaged in conducting research and development (R&D) to develop cannabis oil formulas, medical-grade vaporizers, and various non-smoking consumption solutions.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Kanabo Group PLC is 7.9%, which is below its 3-year median of 15.3%.
Over the last 3 years, Kanabo Group PLC’s Gross Margin has increased from -26.7% to 7.9%. During this period, it reached a low of -26.7% on Jun 30, 2021 and a high of 33.3% on Jun 30, 2022.
